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ABSTRACT
OBJECTIVES
To assess the overall effect of vitamin D
supplementation on risk of acute respiratory tract
infection, and to identify factors modifying this effect.
DESIGN
Systematic review and meta-analysis of individual
participant data (IPD) from randomised controlled
trials.
DATA SOURCES
Medline, Embase, the Cochrane Central Register of
Controlled Trials, Web of Science, ClinicalTrials.gov, and
the International Standard Randomised Controlled Trials
Number registry from inception to December 2015.
ELIGIBILITY CRITERIA FOR STUDY SELECTION
Randomised, double blind, placebo controlled trials of
supplementation with vitamin D3 or vitamin D2 of any
duration were eligible for inclusion if they had been
approved by a research ethics committee and if data
on incidence of acute respiratory tract infection were
collected prospectively and prespecified as an efficacy
outcome.
RESULTS
25 eligible randomised controlled trials (total 11 321
participants, aged 0 to 95 years) were identified. IPD
were obtained for 10 933 (96.6%) participants. Vitamin
D supplementation reduced the risk of acute

WHAT IS ALREADY KNOWN ON THIS TOPIC
Randomised controlled trials of vitamin D supplementation for the prevention of
acute respiratory tract infection have yielded conflicting results
Individual participant data (IPD) meta-analysis has the potential to identify factors
that may explain this heterogeneity, but this has not previously been performed

WHAT THIS STUDY ADDS
Meta-analysis of IPD from 10 933 participants in 25 randomised controlled trials
showed an overall protective effect of vitamin D supplementation against acute
respiratory tract infection (number needed to treat (NNT)=33)
Benefit was greater in those receiving daily or weekly vitamin D without additional
bolus doses (NNT=20), and the protective effects against acute respiratory tract
infection in this group were strongest in those with profound vitamin D deficiency at
baseline (NNT=4)
These findings support the introduction of public health measures such as food
fortification to improve vitamin D status, particularly in settings where profound
vitamin D deficiency is common
the bmj | BMJ 2017;356:i6583 | doi: 10.1136/bmj.i6583

respiratory tract infection among all participants
(adjusted odds ratio 0.88, 95% confidence interval
0.81 to 0.96; P for heterogeneity <0.001). In subgroup
analysis, protective effects were seen in those
receiving daily or weekly vitamin D without additional
bolus doses (adjusted odds ratio 0.81, 0.72 to 0.91)
but not in those receiving one or more bolus doses
(adjusted odds ratio 0.97, 0.86 to 1.10; P for
interaction=0.05). Among those receiving daily or
weekly vitamin D, protective effects were stronger in
those with baseline 25-hydroxyvitamin D levels <25
nmol/L (adjusted odds ratio 0.30, 0.17 to 0.53) than in
those with baseline 25-hydroxyvitamin D levels ≥25
nmol/L (adjusted odds ratio 0.75, 0.60 to 0.95; P for
interaction=0.006). Vitamin D did not influence the
proportion of participants experiencing at least one
serious adverse event (adjusted odds ratio 0.98, 0.80
to 1.20, P=0.83). The body of evidence contributing to
these analyses was assessed as being of high quality.
CONCLUSIONS
Vitamin D supplementation was safe and it protected
against acute respiratory tract infection overall.
Patients who were very vitamin D deficient and those
not receiving bolus doses experienced the most
benefit.
SYSTEMATIC REVIEW REGISTRATION
PROSPERO CRD42014013953.

Introduction
Acute respiratory tract infections are a major cause of
global morbidity and mortality and are responsible for
10% of ambulatory and emergency department visits in
the USA1 and an estimated 2.65 million deaths worldwide in 2013.2 Observational studies report consistent
independent associations between low serum concentrations of 25-hydroxyvitamin D (the major circulating
vitamin D metabolite) and susceptibility to acute respiratory tract infection.3 4 25-hydroxyvitamin D supports
induction of antimicrobial peptides in response to both
viral and bacterial stimuli,5-7 suggesting a potential
mechanism by which vitamin D inducible protection
against respiratory pathogens might be mediated. Vitamin D metabolites have also been reported to induce
other innate antimicrobial effector mechanisms,
including induction of autophagy and synthesis of
reactive nitrogen intermediates and reactive oxygen
intermediates.8 These epidemiological and in vitro data
1
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have prompted numerous randomised controlled trials
to determine whether vitamin D supplementation can
decrease the risk of acute respiratory tract infection. A
total of five aggregate data meta-analyses incorporating
data from up to 15 primary trials have been conducted
to date, of which two report statistically significant protective eﬀects9 10 and three report no statistically significant eﬀects.11-13 All but one of these aggregate data
meta-analyses11 reported statistically significant heterogeneity of eﬀect between primary trials.
This heterogeneity might have arisen as a result of
variation in participant characteristics and dosing regimens between trials, either of which may modify the
eﬀects of vitamin D supplementation on immunity to
respiratory pathogens.14 People with chronic obstructive pulmonary disease who have lower baseline vitamin D status have been reported to derive greater
clinical benefit from supplementation than those with
higher baseline status,15 16 and participant characteristics such as age and body mass index have been
reported to modify the 25-hydroxyvitamin D response to
vitamin D supplementation.17 18 Treatment with large
boluses of vitamin D has been associated with reduced
eﬃcacy for non-classic eﬀects,9 and in some cases an
increased risk of adverse outcomes.19 While study level
factors are amenable to exploration through aggregate
data meta-analysis of published data, potential eﬀect
modifiers operating at an individual level, such as baseline vitamin D status, can only be explored using individual participant data (IPD) meta-analysis. This is
because subgroups are not consistently disaggregated
in trial reports, and adjustments for potential confounders cannot be applied similarly across trials.20 To
identify factors that might explain the observed heterogeneity of results from randomised controlled trials, we
undertook an IPD meta-analysis based on all 25 randomised controlled trials of vitamin D supplementation
for prevention of acute respiratory tract infection that
were completed up to the end of December 2015.

Methods
Protocol and registration
The methods were prespecified in a protocol that was registered with the PROSPERO International Prospective
Register of Systematic Reviews (www.crd.york.ac.uk/
PROSPERO/display_record.asp?ID=CRD42014013953).
Approval by a research ethics committee to conduct this
meta-analysis was not required in the UK; local ethical
permission to contribute deidentified IPD from primary
trials was required and obtained for studies by Camargo
et al21 (the ethics review committee of the Mongolian Ministry of Health), Murdoch et al22 (Southern Health and
Disability Ethics Committee, reference URB/09/10/050/
AM02), Rees et al23 (Committee for the Protection of
Human Subjects, Dartmouth College, USA; protocol No
24381), Tachimoto et al24 (ethics committee of the Jikei
University School of Medicine, reference 26-333: 7839),
Tran et al25 (QIMR Berghofer Medical Research Institute
human research ethics committee, P1570), and Urashima
et al26 27 (ethics committee of the Jikei University School of
Medicine, reference 26-333: 7839).
2

Patient and public involvement
Two patient and public involvement representatives
were involved in development of the research questions
and the choice of outcome measures specified in the
study protocol. They were not involved in patient
recruitment, since this is a meta-analysis of completed
studies. Data relating to the burden of the intervention
on participants’ quality of life and health were not
meta-analysed. Where possible, results of this systematic review and meta-analysis will be disseminated to
individual participants through the principal investigators of each trial.
Eligibility criteria
Randomised, double blind, placebo controlled trials of
supplementation with vitamin D3 or vitamin D2 of any
duration were eligible for inclusion if they had been
approved by a research ethics committee and if data on
incidence of acute respiratory tract infection were collected prospectively and prespecified as an eﬃcacy outcome. The last requirement was imposed to minimise
misclassification bias (prospectively designed instruments to capture acute respiratory tract infection events
were deemed more likely to be sensitive and specific for
this outcome). We excluded studies reporting results of
long term follow-up of primary randomised controlled
trials.
Study identification and selection
Two investigators (ARM and DAJ) searched Medline,
Embase, the Cochrane Central Register of Controlled
Trials (CENTRAL), Web of Science, ClinicalTrials.gov,
and the International Standard Randomized Controlled Trials Number (ISRCTN) registry using the
electronic search strategies described in the supplementary material. Searches were regularly updated
up to, and including, 31 December 2015. No language
restrictions were imposed. These searches were supplemented by searches of review articles and reference lists of trial publications. Collaborators were
asked if they knew of any additional trials. Two investigators (ARM and CAC) determined which trials met
the eligibility criteria.
Data collection processes
IPD were requested from the principal investigator for
each eligible trial, and the terms of collaboration were
specified in a data transfer agreement, signed by representatives of the data provider and the recipient (Queen
Mary University of London). Data were deidentified at
source before transfer by email. On receipt, three investigators (DAJ, RLH, and LG) assessed data integrity by
performing internal consistency checks and by attempting to replicate results of the analysis for incidence of
acute respiratory tract infection where this was published in the trial report. Study authors were contacted
to provide missing data and to resolve queries arising
from these integrity checks. Once queries had been
resolved, clean data were uploaded to the main study
database, which was held in STATA IC v12 (College
Station, TX).
doi: 10.1136/bmj.i6583 | BMJ 2017;356:i6583 | the bmj
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Data relating to study characteristics were extracted
for the following variables: setting, eligibility criteria,
details of intervention and control regimens, study
duration, and case definitions for acute respiratory
tract infection. IPD were extracted for the following
variables, where available: baseline data were
requested for age, sex, cluster identifier (cluster randomised trials only), racial or ethnic origin, influenza
vaccination status, history of asthma, history of
chronic obstructive pulmonary disease, body weight,
height (adults and children able to stand) or length
(infants), serum 25-hydroxyvitamin D concentration,
study allocation (vitamin D versus placebo), and
details of any stratification or minimisation variables.
Follow-up data were requested for total number of
acute respiratory tract infections (upper or lower),
upper respiratory tract infections, and lower respiratory tract infections experienced during the trial; time
from first dose of study drug to first acute respiratory
tract infection (upper or lower), upper respiratory tract
infection, or lower respiratory tract infection if applicable; total number of courses of antibiotics taken for
acute respiratory tract infection during the trial; total
number of days oﬀ work or school due to symptoms of
acute respiratory tract infection during the trial; serum
25-hydroxyvitamin D concentration at final follow-up;
duration of follow-up; number and nature of serious
adverse events; number of potential adverse reactions
(incident hypercalcaemia or renal stones); and participant status at end of the trial (completed, withdrew,
lost to follow-up, died).

Risk of bias assessment for individual studies
We used the Cochrane Collaboration risk of bias tool28 to
assess sequence generation; allocation concealment;
blinding of participants, staﬀ, and outcome assessors;
completeness of outcome data; and evidence of selective
outcome reporting and other potential threats to validity. Two investigators (ARM and DAJ) independently
assessed study quality, except for the three trials by Martineau and colleagues, which were assessed by CAC.
Discrepancies were resolved by consensus.
Definition of outcomes
The primary outcome of the meta-analysis was incidence of acute respiratory tract infection, incorporating
events classified as upper respiratory tract infection,
lower respiratory tract infection, and acute respiratory
tract infection of unclassified location (ie, infection of
the upper respiratory tract or lower respiratory tract, or
both). Secondary outcomes were incidence of upper
and lower respiratory tract infections, analysed separately; incidence of emergency department attendance
or hospital admission, or both for acute respiratory
tract infection; use of antimicrobials for treatment of
acute respiratory tract infection; absence from work or
school due to acute respiratory tract infection; incidence and nature of serious adverse events; incidence
of potential adverse reactions to vitamin D (hypercalcaemia or renal stones); and mortality (acute respiratory tract infection related and all cause).
the bmj | BMJ 2017;356:i6583 | doi: 10.1136/bmj.i6583

Synthesis methods
LG and RLH analysed the data. Our IPD meta-analysis
approach followed published guidelines.20 Initially we
reanalysed all studies separately; the original authors
were asked to confirm the accuracy of this reanalysis
where it had been performed previously, and any discrepancies were resolved. Then we performed both one
step and two step IPD meta-analysis for each outcome
separately using a random eﬀects model adjusted for
age, sex, and study duration to obtain the pooled intervention eﬀect with a 95% confidence interval. We did
not adjust for other covariates because missing values
for some participants would have led to their exclusion
from statistical analyses. In the one step approach, we
modelled IPD from all studies simultaneously while
accounting for the clustering of participants within
studies. In the two step approach we first analysed IPD
for each separate study independently to produce an
estimate of the treatment eﬀect for that study; we then
synthesised these data in a second step.20 For the one
step IPD meta-analysis we assessed heterogeneity by
calculation of the standard deviation of random eﬀects;
for the two step IPD meta-analysis we summarised heterogeneity using the I2 statistic. We calculated the number needed to treat to prevent one person from having
any acute respiratory tract infection (NNT) using the
Visual Rx NNT calculator (www.nntonline.net/visualrx/), where meta-analysis of dichotomous outcomes
revealed a statistically significant beneficial eﬀect of
allocation to vitamin D compared with placebo.
Exploration of variation in effects
To explore the causes of heterogeneity and identify factors modifying the eﬀects of vitamin D supplementation,
we performed prespecified subgroup analyses by extending the one step meta-analysis framework to include
treatment-covariate interaction terms. Subgroups were
defined according to baseline vitamin D status (serum
25-hydroxyvitamin D <25 v ≥25 nmol/L), vitamin D dosing
regimen (daily or weekly without bolus dosing versus a
regimen including at least one bolus dose of at least
30 000 IU vitamin D), dose size (daily equivalent <800
IU, 800-1999 IU, ≥2000 IU), age (≤1 year, 1.1-15.9 years,
16-65 years, >65 years), body mass index (<25 v ≥25), and
presence compared with absence of asthma, chronic
obstructive pulmonary disease, and previous influenza
vaccination. To ensure that reported subgroup eﬀects
were independent, we adjusted interaction analyses for
potential confounders (age, sex, and study duration).
The 25 nmol/L cut-oﬀ for baseline 25-hydroxyvitamin D
concentration in subgroup analyses was selected on the
grounds that it is the threshold for vitamin D deficiency
defined by the UK Department of Health,29 and the level
below which participants in clinical trials have experienced the most consistent benefits of supplementation.30
We also performed an exploratory analysis investigating
eﬀects in subgroups defined using the 50 nmol/L and 75
nmol/L cut-oﬀs for baseline circulating 25-hydroxyvitamin D concentration, because observational studies have
reported that less profound states of vitamin D deficiency
may also associate independently with an increased risk
3
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of acute respiratory tract infection.31 32 To minimise the
chance of type 1 error arising from multiple analyses, we
inferred statistical significance for subgroup analyses
only where P values for treatment-covariate interaction
terms were <0.05.

Quality assessment across studies
For the primary analysis we investigated the likelihood
of publication bias through the construction of a contour enhanced funnel plot.33 We used the five GRADE
considerations (study limitations, consistency of eﬀect,
imprecision, indirectness, and publication bias)34 to
assess the quality of the body of evidence contributing
to analyses of the primary eﬃcacy outcome and major
safety outcome of our meta-analysis (see supplementary table S3).
Additional analyses
We conducted sensitivity analyses excluding IPD from
trials where acute respiratory tract infection was a secondary outcome (as opposed to a primary or co-primary
outcome), and where risk of bias was assessed as being
unclear. We also conducted a responder analysis in participants randomised to the intervention arm of
included studies for whom end study data on
25-hydroxyvitamin D were available, comparing risk of
acute respiratory tract infection in those who attained a
serum level of 75 nmol/L or more compared with those
who did not.
Results
Study selection and IPD obtained
Our search identified 532 unique studies that were
assessed for eligibility; of these, 25 studies with a total
of 11 321 randomised participants fulfilled the eligibility
criteria (fig 1). IPD were sought and obtained for all 25
studies. Outcome data for the primary analysis of proportion of participants experiencing at least one acute
Studies identified through database searches
(n=717):
Medline (n=261)
Cochrane CENTRAL (n=146)
Embase (n=52)
Web of Science (n=258)

Additional studies identified
through other sources, including
contact with researchers (n=3)

Unique studies after duplicates removed (n=532)
Excluded (not relevant, review article, not randomised controlled trials,
acute respiratory tract infection not prespecified as efficacy outcome) (n=507)
Studies with total of 11 321 randomised participants eligible; IPD sought for all (n=25)
Available data:
IPD obtained for eligible studies (n=25)
Randomised participants with outcome data for primary analysis (n=10 933)
Randomised participants with missing outcome data for primary analysis (n=388)
Analysis, proportion experiencing ≥1 acute respiratory tract infections:
One step: data from 10 933 participants in 25 studies analysed
Two step: data from 10 899 participants in 24 studies analysed (34 participants in one study
excluded – treatment effect not estimable)

Fig 1 | Flow of study selection. IPD=individual participant data
4

respiratory tract infection were obtained for 10 933
(96.6%) of the randomised participants.

Study and participant characteristics
Table 1 presents the characteristics of eligible studies
and their participants. Trials were conducted in 14
countries on four continents and enrolled participants
of both sexes from birth to 95 years of age. Baseline
serum 25-hydroxyvitamin D concentrations were determined in 19/25 trials: mean baseline concentration
ranged from 18.9 to 88.9 nmol/L. Baseline characteristics of participants randomised to intervention and control were similar (see supplementary table S1). All
studies administered oral vitamin D3 to participants in
the intervention arm: this was given as bolus doses
every month to every three months in seven studies,
weekly doses in three studies, a daily dose in 12 studies,
and a combination of bolus and daily doses in three
studies. Study duration ranged from seven weeks to 1.5
years. Incidence of acute respiratory tract infection was
the primary or co-primary outcome for 14 studies and a
secondary outcome for 11 studies.
IPD integrity was confirmed by replication of primary
analyses in published papers where applicable. The
process of checking IPD identified three typographical
errors in published reports. For the 2012 trial by
Manaseki-Holland et al,35 the correct number of repeat
episodes of chest radiography confirmed pneumonia
was 134, rather than 138 as reported. For the trial by
Dubnov-Raz et al,36 the number of patients randomised
to the intervention arm was 27, rather than 28 as
reported. For the trial by Laaksi et al,37 the proportion of
men randomised to placebo who did not experience any
acute respiratory tract infection was 30/84, rather than
30/80 as reported.
Risk of bias within studies
Supplementary table S2 provides details of the risk of
bias assessment. All but two trials were assessed as
being at low risk of bias for all aspects assessed. Two
trials were assessed as being at unclear risk of bias
owing to high rates of loss to follow-up. In the trial by
Dubnov-Raz et al,36 52% of participants did not complete all symptom questionnaires. In the trial by Laaksi
et al,37 37% of randomised participants were lost to follow-up.
Incidence of acute respiratory tract infection
Overall results
Table 2 presents the results of the one step IPD
meta-analysis testing the eﬀects of vitamin D on the
proportion of all participants experiencing at least one
acute respiratory tract infection, adjusting for age, sex,
and study duration. Vitamin D supplementation
resulted in a statistically significant reduction in the
proportion of participants experiencing at least one
acute respiratory tract infection (adjusted odds ratio
0.88, 95% confidence interval 0.81 to 0.96, P=0.003; P
for heterogeneity <0.001; NNT=33, 95% confidence
interval 20 to 101; 10 933 participants in 25 studies; see
Cates plot, supplementary figure S1). Statistically
doi: 10.1136/bmj.i6583 | BMJ 2017;356:i6583 | the bmj
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Australia
(1 year)
Canada
(8 weeks)

Tran 201425

Goodall 2014 47

USA
(13 months,
average)

Rees 201323

65.3 (17.3)
(24.7-120.6)

49.3 (23.2)
(8.0-135.0)

72.1 (22.1)
(13.0-142.0)

18.9 (9.7)
(3.3-61.2)

ND

49.8 (29.2)
(9.0-159.7)

41.7 (13.5)
(12.6-105.0)
ND

RIA (IDS), DEQAS 62.5 (21.3)
(30.2-171.6)

CLA (DiaSorin),
ISO9001

71.7 (6.9)
CLA (DiaSorin),
(60.3-85.2) DEQAS
19.6 (2.2)
-(17.0-33.0)

61.2 (6.6)
(47.1-77.9)

2.8 (1.0)
(1.3-4.8)

53.1 (13.1) CLA (DiaSorin),
(20.0-77.0) DEQAS

Sweden
(1 year)

Adults with
increased
susceptibility to
ARTI (38:102)
Children with
recurrent acute
otitis media
(64:52)
Adults with
previous colorectal
adenoma
(438:321*)
Healthy older
adults (343:301)
Healthy university
students (218:382)

LC-MS/MS,
DEQAS

--

RIA (Diasorin),
DEQAS

48.1 (9.7)
(18.0-67.6)

Marchisio 201346 Italy
(6 months)

Bergman 201245

Murdoch 201222

ND

ND

63.7 (25.5)
(16.0-156.0)

1039:1040

ND

430:214
300:300

--

399:360

58:58

70:70

161:161

143:104

1524:1522

66/643 (10.3)

0/759 (0.0)

2/116 (1.7)

15/131 (11.45)

5/322 (1.6)

192/245 (78.4)

ND

91:91

24:24

0/48 (0.0)

31/182 (17.0)

80:84

224:229

217:213

84:78

0/73 (0.0)

--

--

3/150 (2.0)

Mean (SD)
No in
baseline level, Baseline level intervention:
nmol/L (range) <25 nmol/L (%) control group

EIA (IDS OCTEIA) 75.9 (18.7)
(41.9-129.0)
RIA (BioSource
88.9 (38.2)
Europe), RIQAS
(31.5-184.7)
-ND

--

--

LC-MS/MS,
DEQAS

Mongolia
(7 weeks)

Camargo 201221

67.9 (8.3)
(48.086.0)
0.5 (0.3)
(0.0-1.0)

19.1 (0.6)
(18.0-21.0)
10.9 (3.3)
(6.0-17.0)
0.1 (0.0)
(0.0-0.3)

1.1 (0.8)
(0.1-3.3)

10.2 (2.3)
(6.0-15.0)

57.9 (13.6) RIA (DiaSorin),
(21.4-80.6) DEQAS

10.0 (0.9)
(7.0-12.7)

Infants (1591:1455)

Afghanistan
(1.5 years)

ManasekiHolland 201235

25(OH)D
Mean (SD)
age, years Assay, EQA
(range)
scheme

3rd/4th grade
schoolchildren
(129:118)
New Zealand Healthy adults
(1.5 years)
(81:241)

Adults with COPD
(145:37)

Belgium
(1 year)

Lehouck 201215

Trilok-Kumar
201144

Majak 201143

Military conscripts
(164:0)
Children with
asthma (32:16)
Low birthweight
infants (970:1109)

Finland
(6 months)
Poland
(6 months)
India
(6 months)

Laaksi 201037

Preschool children
with pneumonia
(257:196)

Afghanistan
(3 months)

Schoolchildren
(242:188)

Urashima 201027 Japan
(4 months)

ManasekiHolland 2010 42

Healthy adults
(34:128)

Participants
(male:female)

USA
(3 months)

Li-Ng 200941

Reference

Setting
(study
duration)

Table 1 | Characteristics of the 25 eligible trials and their participants

0.75 mg bolus v 1.5 mg
bolus monthly, placebo
0.25 mg weekly (factorial
with gargling), placebo

25 μg daily, placebo

25 μg daily, placebo

2×5 mg bolus monthly then
2.5 mg bolus monthly,
placebo
100 μg daily, placebo

7.5 μg daily, placebo

2.5 mg bolus 3-monthly,
placebo

2.5 mg bolus monthly,
placebo

35 μg weekly, placebo

12.5 μg daily, placebo

10 μg daily, placebo

2.5 mg bolus once, placebo

30 μg daily, placebo

50 μg daily, placebo

Oral dose of vitamin D3

334/430 (77.7)

157/162 (96.9)

No entering
primary
analysis/No
randomised (%)

164/164 (100.0)

URTI: self reported
cold
URTI: self reported
cold

URTI: assessed
from daily symptom
diary

URTI: doctor
diagnosed acute
otitis media

116/116 (100.0)

Primary

(Continued)

492/600 (82.0)

Secondary 594/644 (92.2)

Secondary 759/759 (100.0)

Primary

URTI: assessed with Secondary 124/140 (88.6)
symptom score

322/322 (100.0)

244/247 (98.8)

3011/3046
(98.9)

Secondary 175/182 (96.2)

Secondary 2064/2079
(99.3)

Secondary 48/48 (100.0)

Primary

Secondary 453/453 (100.0)

Primary

Primary

Outcome
type

LRTI: pneumonia
Primary
confirmed by chest
radiography
ARTI: parent
Secondary
reported “chest
infections or colds”
URTI: assessed with Primary
symptom score

ARTI: medical
record diagnosis of
events resulting in
hospital admission
URTI: self report

URTI: ≥2 URTI
symptoms in
absence of allergy
symptoms
URTI: influenza A/B
diagnosed by RIDT
or RIDT-negative ILI
LRTI: repeat episode
of pneumonia—agespecific tachypnoea
without wheeze
ARTI: medical
record diagnosis
ARTI: self report

Definition

ARTI
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New Zealand
(9 months:
3 months in
pregnancy +
6 months in
infancy)
UK (1 year)

Healthy adults
(14:20)
Adolescent
swimmers with
vitamin D
insufficiency
(34:20)
Adults with asthma
(130:278)
Children with
asthma (50:39)
Older care home
residents (45:62)

Simpson 201551

39.2 (12.9)
(18.0-85.0)
9.9 (2.3)
(6.0-15.0)
80.7 (9.9)
(60.095.0)

32.2 (12.2)
(18.0-52.0)
15.2 (1.6)
(12.9-18.6)

CLA (DiaSorin),
VDSP
RIA (DiaSorin),
CAP
LC-MS/MS, VDSP

LC-MS/MS,
DEQAS
RIA (DiaSorin),
DEQAS

67.1 (13.0) LC-MS/MS,
(21.4-94.0) DEQAS

LC-MS/MS,
DEQAS

LC-MS/MS,
DEQAS

LC-MS/MS,
DEQAS

--

47.0 (16.9)
(10.0-74.6)
74.9 (24.6)
(20.0-187.2)
57.3 (22.7)
(11.7-106.1)

67.9 (23.0)
(32.0-132.0)
60.4 (11.9)
(28.0-74.6)

42.9 (23.0)
(0.0-128.0)

49.6 (24.7)
(0.0-139.0)

46.1 (25.7)
(0.0-160.0)

54.8 (25.8)
(8.0-128.0)

ND

54:35
55:52

1/89 (1.1)
12/107 (11.2)

201:207

27:27

0/54 (0.0)

55/408 (13.5)

18:16

137:103

125:125

122:118

2.5 mg bolus then 100 μg
daily, placebo
20 μg daily, first 2 months,
placebo
2.5 mg bolus monthly+≤25
μg per day equivalent,
placebo+10-25 μg per day
equivalent

50 μg daily, placebo

Older adults: 2.4 mg bolus
2-monthly+10 μg daily.
Carers: 3 mg 2-monthly,
older adults: placebo+10 μg
daily. Carers: placebo
0.5 mg weekly, placebo

3 mg bolus 2-monthly,
placebo

3 mg bolus 2-monthly,
placebo

50 μg daily, placebo

Oral dose of vitamin D3

Definition

ARTI

Primary

Primary

25/54 (46.3)

34/34 (100.0)

240/240 (100.0)

250/250 (100.0)

240/240 (100.0)

URTI assessed with Secondary 408/408 (100.0)
symptom score
URTI: assessed with Secondary 89/89 (100.0)
symptom score
ARTI: medical
Primary
107/107 (100.0)
record diagnosis

ARTI assessed with
symptom score
URTI assessed with
symptom score

247/247 (100.0)

No entering
primary
analysis/No
randomised (%)

Secondary 236/260 (90.8)

Primary

Outcome
type

URTI: assessed
Coprimary
from daily symptom
diary
URTI: assessed
Coprimary
from daily symptom
diary
URTI and LRTI, both Coprimary
assessed from daily
symptom diary

URTI: influenza A
diagnosed by RIDT
or RIDT negative ILI
173:87 (mothers) Mothers: 25 μg v 50 μg daily ARTI: doctor
164:85 (offspring) Infants: 10 μg v 20 μg daily, diagnosed ARTI
placebo
precipitating
primary care
consultation

148:99

0/33 (0.0)

60/240 (25.0)

36/250 (14.4)

50/240 (20.8)

30/200 (15.0)

--

Mean (SD)
No in
baseline level, Baseline level intervention:
nmol/L (range) <25 nmol/L (%) control group

25(OH)D=25-hydroxyvitamin D; RIDT=rapid influenza diagnostic test; COPD=chronic obstructive pulmonary disease; D3, vitamin D3 (cholecalciferol); ARTI=acute respiratory tract infection; CAP=College of American Pathologists;
CLA=chemiluminescent assay; DEQAS=Vitamin D External Quality Assessment Scheme; EIA=enzyme immunoassay; EQA=external quality assessment; LC-MS/MS=liquid chromatography tandem-mass spectrometry; RIA=radioimmunoassay;
URTI=upper respiratory tract infection; LRTI=lower respiratory tract infection; ILI=influenza-like illness; RIQAS=Randox International Quality Assessment Scheme; VDSP=Vitamin D Standardisation Program of the Office of Dietary Supplements,
National Institutes of Health, USA.
1 μg vitamin D3 =40 international units (IU); 25(OH)D concentrations reported in ng/mL were converted to nmol/L (multiplying by 2.496)
*Sex missing for two participants randomised to intervention arm and subsequently excluded from analysis owing to lack of outcome data.

Denlinger 201652 USA
(28 weeks)
Japan
Tachimoto
(6 months)
201624
USA (1 year)
Ginde, 201653

Dubnov-Raz
201536

Older adults and
their carers
(82:158)

Australia
(17 weeks)
Israel
(12 weeks)

16.5 (1.0)
(15.0-18.0)

64.7 (8.5)
(40.085.0)
Adults with asthma 47.9 (14.4)
(109:141)
(16.0-78.0)

Adults with COPD
(144:96)

25(OH)D
Mean (SD)
age, years Assay, EQA
(range)
scheme

Pregnant women
unborn
and offspring
(0:260 (mothers)
121:128 (offspring))

High school
students (162:85)

Participants
(male:female)

UK (1 year)
Martineau
2015c50 (ViDiFlu)

UK (1 year)
Martineau
2015b49 (ViDiAs)

Martineau
2015a16 (ViDiCO)

Grant 2014 48

Urashima 201426 Japan
(2 months)

Reference

Setting
(study
duration)

Table 1 | Characteristics of the 25 eligible trials and their participants
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Table 2 | One step individual participant data meta-analysis, proportion of participants experiencing at least one acute respiratory tract infection
(ARTI): overall and by subgroup
Variables

Overall
Baseline 25(OH)D (nmol/L):
<25
≥25
Dosing regimen type:
Bolus dose ≥30 000 IU given
Bolus dose not given
Daily dose equivalent (μg):
<20
20-50
≥50
Age (years):
≤1
1.1-15.9
16-65
>65
Body mass index (kg/m2):
<25
≥25
Asthma:
No
Yes
COPD:
No
Yes
Influenza vaccination:
No
Yes

No of
trials*

Proportion with ≥1
ARTI, control group (%)

Proportion with ≥1 ARTI,
intervention group (%)

Adjusted odds
ratio (95% CI)†

P value

P value for
interaction

25

2204/5225 (42.2)

2303/5708 (40.3)

0.88 (0.81 to 0.96)

0.003

--

14
19

137/249 (55.0)
1027/1639 (62.7)

117/289 (40.5)
1179/1995 (59.1)

0.58 (0.40 to 0.82)
0.89 (0.77 to 1.04)

0.002
0.15

0.01

10
15

994/2786 (35.7)
1210/2439 (49.6)

1097/3014 (36.4)
1206/2694 (44.8)

0.97 (0.86 to 1.10)
0.81 (0.72 to 0.91)

0.67
<0.001

0.05

5
9
11

629/1321 (47.6)
945/2796 (33.8)
630/1108 (56.9)

619/1435 (43.1)
1023/3077 (33.2)
661/1196 (55.3)

0.80 (0.68 to 0.94)
0.90 (0.79 to 1.01)
0.98 (0.81 to 1.18)

0.006
0.08
0.84

0.12

4
8
17
11

832/2744 (30.3)
241/513 (47.0)
854/1459 (58.5)
277/509 (54.4)

854/2827 (30.2)
194/566 (34.3)
885/1592 (55.6)
370/723 (51.2)

0.94 (0.83 to 1.06)
0.60 (0.46 to 0.77)
0.93 (0.79 to 1.10)
0.86 (0.67 to 1.09)

0.33
<0.001
0.41
0.21

0.61

19
17

972/1943 (50.0)
659/1039 (63.4)

956/2074 (46.1)
754/1235 (61.1)

0.85 (0.74 to 0.97)
0.95 (0.79 to 1.14)

0.02
0.58

0.29

11
11

518/1008 (51.4)
296/534 (55.4)

520/1101 (47.2)
285/542 (52.6)

0.82 (0.68 to 0.99)
0.95 (0.73 to 1.25)

0.04
0.73

0.48

7
6

477/763 (62.5)
122/230 (53.0)

493/791 (62.3)
120/238 (50.4)

1.00 (0.80 to 1.26)
0.84 (0.57 to 1.24)

0.98
0.38

0.38

10
10

255/373 (68.4)
564/779 (72.4)

253/407 (62.2)
577/826 (69.9)

0.74 (0.52 to 1.03)
0.86 (0.68 to 1.09)

0.08
0.22

0.51

25(OH)D=25-hydroxyvitamin D; COPD=chronic obstructive pulmonary disease; 1 μg vitamin D3 =40 international units (IU).
*Some trials did not contribute data to a given subgroup, either because individuals within that subgroup were not represented or because data relating to the potential effect modifier were not
recorded; accordingly the number of trials represented varies between subgroups.
†Adjusted for age, sex, and study duration.

significant protective eﬀects of vitamin D were also seen
for one step analyses of acute respiratory tract infection
rate (adjusted incidence rate ratio 0.96, 95% confidence
interval 0.92 to 0.997, P=0.04; P for heterogeneity
<0.001; 10 703 participants in 25 studies) but not for
analysis of time to first acute respiratory tract infection
(adjusted hazard ratio 0.95, 95% confidence interval
0.89 to 1.01, P=0.09; P for heterogeneity <0.001; 9108
participants in 18 studies). Two step analyses also
showed consistent eﬀects for the proportion of participants experiencing at least one acute respiratory tract
infection (adjusted odds ratio 0.80, 0.69 to 0.93,
P=0.004; P for heterogeneity 0.001; 10 899 participants
in 24 studies; fig 2), acute respiratory tract infection rate
(adjusted incidence rate ratio 0.91, 0.84 to 0.98,
P=0.018; P for heterogeneity <0.001; 10 703 participants
in 25 studies), and time to first acute respiratory tract
infection (adjusted hazard ratio 0.92, 0.85 to 1.00,
P=0.051; P for heterogeneity 0.14; 9108 participants in
18 studies). This evidence was assessed as being of high
quality (see supplementary table S3).

Subgroup analyses
To explore reasons for heterogeneity, we conducted
subgroup analyses to investigate whether eﬀects of
vitamin D supplementation on risk of acute respiratory
the bmj | BMJ 2017;356:i6583 | doi: 10.1136/bmj.i6583

tract infection diﬀered according to baseline vitamin D
status, dosing frequency, dose size, age, body mass
index, the presence or absence of comorbidity (asthma
or chronic obstructive pulmonary disease), and influenza vaccination status. Race or ethnicity was not
investigated as a potential eﬀect modifier, as data for
this variable were missing for 3680/10 933 (34%) participants and power for subgroup analyses was limited by
small numbers in many racial or ethnic subgroups that
could not be meaningfully combined. Table 2 presents
the results. Subgroup analysis revealed a strong protective eﬀect of vitamin D supplementation among those
with baseline circulating 25-hydroxyvitamin D levels
less than 25 nmol/L (adjusted odds ratio 0.58, 0.40
to 0.82, NNT=8, 5 to 21; 538 participants in 14 studies; within subgroup P=0.002; see Cates plot,
supplementary figure S1) and no statistically significant eﬀect among those with baseline levels of 25 or
more nmol/L (adjusted odds ratio 0.89, 0.77 to 1.04;
3634 participants in 19 studies; within subgroup
P=0.15; P for interaction 0.01). This evidence was
assessed as being of high quality (see supplementary
table S3). An exploratory analysis testing the eﬀects of
vitamin D supplementation in those with baseline
25-hydroxyvitamin D concentrations in the ranges
25-49.9 nmol/L, 50-74.9 nmol/L, and 75 or more nmol/L
7
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Proportion with ≥1 ARTI (%)
Study

Control

Intervention

Adjusted odds ratio
(95% CI)

Weight Adjusted odds ratio
(%)
(95% CI)

Li-Ng 2009

33/76 (43.4)

32/81 (39.5)

3.48

0.85 (0.44 to 1.64)

Urashima 2010

69/167 (41.3)

68/167 (40.7)

5.36

0.90 (0.58 to 1.41)

Manaseki-Holland 2010

126/229 (55.0)

97/224 (43.3)

6.12

0.60 (0.41 to 0.88)

Laaksi 2010

54/84 (64.3)

39/80 (48.8)

3.58

0.51 (0.27 to 0.96)

Majak 2011

11/24 (45.8)

4/24 (16.7)

1.00

0.20 (0.05 to 0.82)

8.69

0.92 (0.77 to 1.11)

3.57

1.00 (0.53 to 1.90)

8.58

1.08 (0.89 to 1.30)

Trilok-Kumar 2011
Lehouck 2012
Manaseki-Holland 2012

458/1030 (44.5) 438/1034 (42.4)
29/89 (32.6)

30/86 (34.9)

245/1505 (16.3) 260/1506 (17.3)

Camargo 2012

53/103 (51.5)

44/141 (31.2)

4.36

0.38 (0.22 to 0.65)

Murdoch 2012

155/161 (96.3)

154/161 (95.7)

1.43

0.97 (0.30 to 3.15)

Bergman 2012

39/62 (62.9)

26/62 (41.9)

2.89

0.42 (0.20 to 0.89)

Marchisio 2013

38/58 (65.5)

26/58 (44.8)

2.84

0.44 (0.21 to 0.95)

Rees 2013

276/360 (76.7)

303/399 (75.9)

6.35

1.03 (0.72 to 1.49)

Tran 2014

96/197 (48.7)

185/397 (46.6)

6.60

0.92 (0.65 to 1.30)

Goodall 2014

80/234 (34.2)

70/258 (27.1)

5.94

0.66 (0.45 to 0.98)

Urashima 2014

17/99 (17.2)

32/148 (21.6)

3.41

1.43 (0.73 to 2.78)

Grant 2014

53/80 (66.3)

94/156 (60.3)

4.12

0.77 (0.43 to 1.36)

Martineau 2015 (ViDiCO)

75/118 (63.6)

76/122 (62.3)

3.98

0.87 (0.48 to 1.57)

Martineau 2015 (ViDiAs)

93/125 (74.4)

85/125 (68.0)

3.74

0.71 (0.38 to 1.31)

Martineau 2015 (ViDiFlu)

58/103 (56.3)

83/137 (60.6)

4.38

1.13 (0.66 to 1.95)

Dubnov-Raz 2015

10/11 (90.9)

10/14 (71.4)

0.28

0.23 (0.01 to 3.82)

Denlinger 2016

93/207 (44.9)

110/201 (54.7)

5.86

1.52 (1.02 to 2.28)

Tachimoto 2016

5/35 (14.3)

4/54 (7.4)

1.01

0.45 (0.11 to 1.89)

Ginde 2016

24/52 (46.2)

17/55 (30.9)

2.44

0.44 (0.19 to 1.02)

Simpson 2015

14/16 (87.5)

16/18 (88.9)

0.00

Excluded

100.00

0.80 (0.69 to 0.93)

Overall: I2=53.3%, P=0.001
Note: Weights are from random effects analysis

0.125

0.25

0.5

1

2

4

Fig 2 | Two step individual participant data meta-analysis: proportion of participants experiencing at least one acute respiratory
tract infection (ARTI). Data from trial by Simpson et al were not included in this two step meta-analysis, as an estimate for the
effect of the intervention in the study could not be obtained in the regression model owing to small sample size

did not reveal evidence of a statistically significant
interaction (see supplementary table S4).
Meta-analysis of data from trials in which vitamin D
was administered using a daily or weekly regimen without additional bolus doses revealed a protective eﬀect
against acute respiratory tract infection (adjusted odds
ratio 0.81, 0.72 to 0.91, NNT=20, 13 to 43; 5133 participants in 15 studies; within subgroup P<0.001; see Cates
plot, supplementary figure S1). No such protective eﬀect
was seen among participants in trials where at least one
bolus dose of vitamin D was administered (adjusted
odds ratio 0.97, 0.86 to 1.10; 5800 participants in 10
studies; within subgroup P=0.67; P for interaction 0.05).
This evidence was assessed as being of high quality (see
supplementary table S3). P values for interaction were
more than 0.05 for all other potential eﬀect modifiers
investigated. For both of these subgroup analyses,
broadly consistent eﬀects were observed for event rate
analysis (see supplementary table S5) and survival
analysis (see supplementary table S6).
Having identified two potential factors that modified
the influence of vitamin D supplementation on risk of
acute respiratory tract infection (ie, baseline vitamin D
status and dosing frequency), we then proceeded to
investigate whether these factors were acting as
independent eﬀect modifiers, or whether they were
8

confounded by each other or by another potential eﬀect
modifier, such as age. Dot plots revealed a trend towards
lower median baseline serum 25-hydroxyvitamin D concentration and higher median age for studies employing
bolus compared with daily or weekly dosing (see supplementary figures S2 and S3). To establish which of these
potential eﬀect modifiers was acting independently, we
repeated the analysis to include treatment-covariate
interaction terms for baseline vitamin D status, dosing
frequency, and age. In this model, interaction terms for
baseline vitamin D status and dosing frequency were
statistically significant (P=0.01 and P=0.004, respectively), but the interaction term for age was not (P=0.20),
consistent with the hypothesis that baseline vitamin D
status and dosing frequency, but not age, independently
modified the eﬀect of vitamin D supplementation on risk
of acute respiratory tract infection.
We then proceeded to stratify the subgroup analysis
presented in table 2 according to dosing frequency, to
provide a “cleaner” look at the results of subgroup
analyses under the assumption that use of bolus doses
was ineﬀective. Table 3 presents the results: these
reveal that daily or weekly vitamin D treatment was
associated with an even greater degree of protection
against acute respiratory tract infection among participants with baseline circulating 25-hydroxyvitamin D
doi: 10.1136/bmj.i6583 | BMJ 2017;356:i6583 | the bmj
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994/2786 (35.7)

73/142 (51.4)
550/910 (60.4)

.
467/1931 (24.2)
527/855 (61.6)

321/1634 (19.6)
50/100 (50.0)
432/678 (63.7)
191/374 (51.1)

215/372 (57.8)
406/677 (60.0)

303/484 (62.6)
224/371 (60.4)

410/632 (64.9)
117/223 (52.5)

119/163 (73.0)
286/396 (72.2)

10

8
8

.
3
7

2
1
8
8

8
8

5
4

5
4

5
5

121/178 (68.0)
294/421 (69.8)

436/656 (66.5)
119/231 (51.5)

323/523 (61.8)
232/364 (63.7)

231/417 (55.4)
509/867 (58.7)

322/1637 (19.7)
35/93 (37.6)
466/716 (65.1)
274/568 (48.2)

.
542/2127 (25.5)
555/887 (62.6)

77/162 (47.5)
663/1121 (59.1)

1097/3014 (36.4)

Proportion with ≥1
ARTI, intervention
group (%)

--‡
.

--‡
--‡

0.95 (0.71 to 1.28)
1.18 (0.85 to 1.65)

1.01 (0.72 to 1.40)
1.00 (0.80 to 1.25)

0.99 (0.83 to 1.19)
0.62 (0.35 to 1.11)
1.15 (0.90 to 1.48)
0.85 (0.65 to 1.12)

.
0.95 (0.81 to 1.10)
1.03 (0.83 to 1.28)

0.82 (0.51 to 1.33)
1.02 (0.83 to 1.24)

0.97 (0.86 to 1.10)

Adjusted odds
ratio (95% CI)†

--‡
.

--‡
--‡

0.75
0.32

0.97
0.98

0.93
0.11
0.27
0.25

.
0.50
0.81

0.43
0.87

0.67

P value

--‡
.

--‡
--‡

0.40

0.70

0.72

0.56

0.42

--

P value for
interaction

5
5

2
2

6
7

11
9

2
7
9
3

5
6
4

6
11

15

No of
trials*

136/210 (64.8)
278/383 (72.6)

67/131 (51.1)
5/7 (71.4)

215/524 (41.0)
72/163 (44.2)

757/1571 (48.2)
253/358 (70.7)

511/1110 (46.0)
191/413 (46.2)
422/781 (54.0)
86/135 (63.7)

629/1321 (47.6)
478/865 (55.3)
103/253 (40.7)

64/107 (59.8)
477/729 (65.4)

1210/2439 (49.6)

Proportion with
≥1 ARTI, control
group (%)

Daily or weekly dosing

132/229 (57.6)
283/405 (69.9)

57/135 (42.2)
1/7 (14.3)

197/578 (34.1)
53/178 (29.8)

725/1657 (43.8)
245/367 (66.8)

532/1190 (44.7)
159/473 (33.6)
419/876 (47.8)
96/155 (61.9)

619/1435 (43.1)
481/950 (50.6)
106/309 (34.3)

40/127 (31.5)
516/874 (59.0)

1206/2694 (44.8)

Proportion with ≥1
ARTI, intervention
group (%)

--‡

--‡
--‡

0.74 (0.58 to 0.95)
0.60 (0.37 to 0.98)

0.82 (0.71 to 0.95)
0.83 (0.59 to 1.17)

0.91 (0.77 to 1.08)
0.59 (0.45 to 0.79)
0.79 (0.63 to 0.99)
0.88 (0.52 to 1.52)

0.80 (0.68 to 0.94)
0.81 (0.66 to 1.01)
0.85 (0.58 to 1.24)

0.30 (0.17 to 0.53)
0.75 (0.60 to 0.95)

0.81 (0.72 to 0.91)

Adjusted odds
ratio (95% CI)†

--‡

--‡
--‡

0.02
0.04

0.009
0.30

0.30
<0.001
0.04
0.66

0.006
0.06
0.39

<0.001
0.02

0.001

P value

--‡

--‡
--‡

0.40

>0.99

0.37

0.82

0.006

--

P value for
interaction

25(OH)D=25-hydroxyvitamin D; COPD=chronic obstructive pulmonary disease; 1 μg vitamin D3 =40 international units (IU).
*Some trials did not contribute data to a given subgroup, either because individuals within that subgroup were not represented or because data relating to the potential effect modifier were not recorded; accordingly the number of trials represented
varies between subgroups.
†Adjusted for age, sex, and study duration.
‡Values could not be estimated as models did not converge.

Overall
Baseline 25(OH)D (nmol/L):
<25
≥25
Daily dose equivalent (μg):
<20
20-50
≥50
Age (years):
≤1
1.1-15.9
16-65
>65
Body mass index (kg/m2):
<25
≥25
Asthma:
No
Yes
COPD:
No
Yes
Influenza vaccination
No
Yes

Variables

No of
trials*

Proportion with
≥1 ARTI, control
group (%)

Bolus dosing

Table 3 | One step individual participant data meta-analysis, proportion of participants experiencing at least one acute respiratory tract infection (ARTI): overall and by subgroup, stratified by dosing
frequency
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concentrations less than 25 nmol/L than in the unstratified analysis (adjusted odds ratio 0.30, 0.17 to 0.53;
NNT=4, 3 to 7; 234 participants in six studies; within
subgroup P<0.001; see Cates plot, supplementary figure S4). Moreover, use of daily or weekly vitamin D also
protected against acute respiratory tract infection
among participants with higher baseline 25-hydroxyvitamin D concentrations (adjusted odds ratio 0.75, 0.60
to 0.95; NNT=15, 9 to 86; 1603 participants in six studies; within subgroup P=0.02; see Cates plot, supplementary figure S4). The P value for interaction for this
subgroup analysis was 0.006, indicating that protective eﬀects of daily or weekly vitamin D supplementation were statistically significantly greater in the
subgroup of participants with profound vitamin D deficiency. No other statistically significant interaction was
seen; notably, bolus dose vitamin D supplementation
did not oﬀer any protection against acute respiratory
tract infection even when administered to those with
circulating 25-hydroxyvitamin D concentrations less
than 25 nmol/L (adjusted odds ratio 0.82, 0.51 to 1.33;
304 participants in eight studies; within subgroup
P=0.43).

Secondary outcomes
Efficacy
Table 4 presents the results of the one step IPD
meta-analysis of secondary outcomes. When all studies
were analysed together, no statistically significant
eﬀect of vitamin D was seen on the proportion of participants with at least one upper respiratory tract infection, lower respiratory tract infection, hospital
admission or emergency department attendance for
acute respiratory tract infection, course of antimicrobials for acute respiratory tract infection, or absence from
work or school due to acute respiratory tract infection.
However, when this analysis was stratified by dosing
frequency, a borderline statistically significant protective eﬀect of daily or weekly vitamin D supplementation
against upper respiratory tract infection was seen
(adjusted odds ratio 0.88, 0.78 to 1.00; 4483 participants
in 11 studies, P=0.05; table 5).

Safety
Use of vitamin D did not influence risk of serious
adverse events of any cause (adjusted odds ratio 0.98,
0.80 to 1.20; 11 224 participants in 25 studies) or death
due to any cause (1.39, 0.85 to 2.27; 11 224 participants in
25 studies) (table 4 ). Instances of potential adverse
reactions to vitamin D were rare. Hypercalcaemia was
detected in 21/3850 (0.5%) and renal stones were diagnosed in 6/3841 (0.2%); both events were evenly represented between intervention and control arms (table 4 ).
Stratification of this analysis by dosing frequency did
not reveal any statistically significant increase in risk of
adverse events with either bolus dosing or daily or
weekly supplementation (table 5).
Risk of bias across studies
A funnel plot for the proportion of participants experiencing at least one acute respiratory tract infection
showed a degree of asymmetry, raising the possibility
that small trials showing adverse eﬀects of vitamin D
might not have been included in the meta-analysis (see
supplementary figure S5).
Responder analyses
Supplementary table S7 presents the results of
responder analyses. Among participants randomised to
the intervention arm of included studies for whom end
study data on 25-hydroxyvitamin D were available, no
diﬀerence in risk of acute respiratory tract infection was
observed between those who attained a serum concentration of 75 or more nmol/L compared with those who
did not.
Sensitivity analyses
IPD meta-analysis of the proportion of participants
experiencing at least one acute respiratory tract infection, excluding two trials assessed as being at unclear
risk of bias,36 37 revealed protective eﬀects of vitamin D
supplementation consistent with the main analysis
(adjusted odds ratio 0.82, 0.70 to 0.95, 10 744 participants, P=0.01). Sensitivity analysis for the same outcome, restricted to the 14 trials that investigated acute
respiratory tract infection as the primary or coprimary

Table 4 | One step individual participant data meta-analysis of secondary outcomes
No of
trials

Proportion with ≥1 event

Outcomes

Control group (%)

Intervention group (%)

Adjusted odds
ratio (95% CI)*

P value

Upper respiratory tract infection
Lower respiratory tract infection
Hospital admission or emergency department attendance due to ARTI
Use of antimicrobials for treatment of ARTI
Work or school absence due to ARTI
Serious adverse event of any cause
Death due to ARTI or respiratory failure
Death due to any infection
Death due to any cause
Hypercalcaemia
Renal stones

19
9
11
9
7
25
25
25
25
14
14

1656/3286 (50.4)
542/3285 (16.5)
47/3886 (1.2)
397/983 (40.4)
321/632 (50.8)
216/5371 (4.0)
7/5330 (0.1)
15/5338 (0.3)
48/5371 (0.9)
9/1739 (0.5)
4/1707 (0.2)

1807/3733 (48.4)
561/3413 (16.4)
40/3986 (1.0)
413/1121 (36.8)
319/684 (46.6)
221/5853 (3.8)
6/5802 (0.1)
16/5812 (0.3)
56/5853 (1.0)
12/2111 (0.6)
2/2134 (0.1)

0.93 (0.83 to 1.03)
0.96 (0.83 to 1.10)
0.83 (0.54 to 1.27)
0.84 (0.69 to 1.03)
0.87 (0.69 to 1.09)
0.98 (0.80 to 1.20)
0.70 (0.23 to 2.20)
0.95 (0.46 to 1.99)
1.39 (0.85 to 2.27)
--†
--†

0.15
0.52
0.39
0.10
0.22
0.83
0.55
0.90
0.18
--†
--†

ARTI=acute respiratory tract infection.
*Adjusted for age, sex, and study duration.
†values could not be estimated as models did not converge.
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0.05
0.88
0.31
0.88
0.86
--†
--†
--†
--†
--†
--†
0.88 (0.78 to 1.00)
0.98 (0.75 to 1.28)
0.87 (0.67 to 1.13)
1.03 (0.71 to 1.48)
0.97 (0.73 to 1.30)
--†
--†
--†
--†
--†
--†
1077/2449 (44.0)
134/1491 (9.0)
210/754 (27.9)
123/273 (45.1)
106/2783 (3.8)
21/2783 (0.8)
3/2765 (0.1)
11/2773 (0.4)
34/1862 (1.8)
1/808 (0.1)
1/1123 (0.1)
1050/2234 (47.0)
118/1396 (8.5)
196/635 (30.9)
102/223 (45.7)
109/2549 (4.3)
19/2549 (0.7)
3/2533 (0.1)
7/2537 (0.3)
43/1805 (2.4)
1/677 (0.1)
4/943 (0.4)
11
5
5
3
15
15
15
15
5
6
8
0.72
0.60
0.16
0.10
0.99
0.40
0.54
0.32
--†
--†
--†
1.03 (0.86 to 1.24)
0.96 (0.82 to 1.13)
0.79 (0.56 to 1.10)
0.78 (0.59 to 1.04)
1.00 (0.74 to 1.35)
1.29 (0.71 to 2.35)
0.61 (0.12 to 3.02)
0.55 (0.17 to 1.80)
--†
--†
--†
8
4
4
4
10
10
10
10
6
8
6

Outcomes

Upper respiratory tract infection
Lower respiratory tract infection
Use of antimicrobials for treatment of ARTI
Work or school absence due to ARTI
Serious adverse event of any cause
Death due to any cause
Death due to ARTI or respiratory failure
Death due to any infection
Hospital admission or emergency department attendance due to ARTI
Hypercalcaemia
Renal stones

ARTI=acute respiratory tract infection.
*Adjusted for age, sex, and study duration.
†Values could not be estimated as model did not converge.

P value

Discussion
In this individual participant data (IPD) meta-analysis
of randomised controlled trials, vitamin D supplementation reduced the risk of experiencing at least one
acute respiratory tract infection. Subgroup analysis
revealed that daily or weekly vitamin D supplementation without additional bolus doses protected against
acute respiratory tract infection, whereas regimens containing large bolus doses did not. Among those receiving daily or weekly vitamin D, protective eﬀects were
strongest in those with profound vitamin D deficiency
at baseline, although those with higher baseline
25-hydroxyvitamin D concentrations also experienced
benefit. This evidence was assessed as being of high
quality, using the GRADE criteria.34 Since baseline vitamin D status and use of bolus doses varied considerably
between studies, our results suggest that the high
degree of heterogeneity between trials may be at least
partly attributable to these factors. Use of vitamin D was
safe: potential adverse reactions were rare, and the risk
of such events was the same between participants randomised to intervention and control arms.
Why might use of bolus dose vitamin D be ineﬀective
for prevention of acute respiratory tract infection? One
explanation relates to the potentially adverse eﬀects of
wide fluctuations in circulating 25-hydroxyvitamin D
concentrations, which are seen after use of bolus doses
but not with daily or weekly supplementation. Vieth
has proposed that high circulating concentrations after
bolus dosing may chronically dysregulate activity of
enzymes responsible for synthesis and degradation of
the active vitamin D metabolite 1,25-dihydroxyvitamin
D, resulting in decreased concentrations of this metabolite in extra-renal tissues.38 Such an eﬀect could attenuate the ability of 25-hydroxyvitamin D to support
protective immune responses to respiratory pathogens.
Increased eﬃcacy of vitamin D supplementation in
those with lower baseline vitamin D status is more readily explicable, based on the principle that people who
are the most deficient in a micronutrient will be the
most likely to respond to its replacement.

730/1284 (56.9)
427/1922 (22.2)
203/367 (55.3)
196/411 (47.7)
115/3070 (3.7)
35/3070 (1.1)
3/3038 (0.1)
5/3040 (0.2)
6/2124 (0.3)
11/1303 (0.8)
1/1011 (0.1)

No of
trials

Proportion with Proportion with ≥1
≥1 event, control event, intervention Adjusted odds
group (%)
ratio (95% CI)*
group (%)

Bolus dosing

Table 5 | One step individual participant data meta-analysis of secondary outcomes, stratified by dosing frequency
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outcome, also revealed protective eﬀects of vitamin D
supplementation consistent with the main analysis
(0.82, 0.68 to 1.00, 5739 participants, P=0.05).

606/1052 (57.6)
424/1889 (22.4)
201/348 (57.8)
219/409 (53.5)
107/2822 (3.8)
29/2822 (1.0)
4/2797 (0.1)
8/2801 (0.3)
4/2081 (0.2)
8/1062 (0.8)
0/764 (0.0)

Proportion with
≥1 event, control
group (%)
No of
trials

Daily or weekly dosing

Proportion with ≥1
event, intervention Adjusted odds
group (%)
ratio (95% CI)*

P value
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Strengths and limitations of this study
Our study has several strengths. We obtained IPD for
all 25 trials identified by our search; the proportion of
randomised participants with missing outcome data
was small (3.4%); participants with diverse characteristics in multiple settings were represented; and
25-hydroxyvitamin D levels were measured using validated assays in laboratories that participated in external quality assessment schemes. Our findings therefore
have a high degree of internal and external validity.
Moreover, the subgroup eﬀects we report fulfil published “credibility criteria” relating to study design,
analysis, and context.39 Specifically, the relevant eﬀect
modifiers were specified a priori and measured at baseline, P values for interaction remained significant after
11
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adjustment for potential confounders, and subgroup
eﬀects were consistent when analysed as proportions
and event rates. Survival analysis revealed consistent
trends that did not attain statistical significance, possibly owing to lack of power (fewer studies contributed
data to survival analyses than to analyses of proportions and event rates). The concepts that vitamin D
supplementation may be more eﬀective when given to
those with lower baseline 25-hydroxyvitamin D levels
and less eﬀective when bolus doses are administered,
are also biologically plausible. A recent Cochrane
review of randomised controlled trials reporting that
vitamin D supplementation reduces the risk of severe
asthma exacerbations, which are commonly precipitated by viral upper respiratory tract infections, adds
further weight to the case for biological plausibility.40
Although the results are consistent with the hypothesis
that baseline vitamin D status and dosing regimen
independently modify the eﬀects of vitamin D supplementation, we cannot exclude the possible influence of
other eﬀect modifiers linked to these two factors. The
risk of residual confounding by other eﬀect modifiers is
increased for analyses where relatively few trials are
represented within a subgroup—for example, where
subgroup analyses were stratified by dosing regimen.
We therefore suggest caution when interpreting the
results in table 3.
Our study has some limitations. One explanation for
the degree of asymmetry seen in the funnel plot is that
some small trials showing adverse eﬀects of vitamin D
might have escaped our attention. With regard to the
potential for missing data, we made strenuous eﬀorts to
identify published and (at the time) unpublished data,
as illustrated by the fact that our meta-analysis includes
data from 25 studies—10 more than the largest aggregate
data meta-analysis on the topic.13 However, if one or two
small trials showing large adverse eﬀects of vitamin D
were to emerge, we do not anticipate that they would
greatly alter the results of the one step IPD meta-analysis, since any negative signal from a modest number of
additional participants would likely be diluted by the
robust protective signal generated from analysis of data
from nearly 11 000 participants. A second limitation is
that our power to detect eﬀects of vitamin D supplementation was limited for some subgroups (eg, individuals
with baseline 25-hydroxyvitamin D concentrations <25
nmol/L receiving bolus dosing regimens) and for some
secondary outcomes (eg, incidence of lower respiratory
tract infection). Null and borderline statistically significant results for analyses of these outcomes may have
arisen as a consequence of type 2 error. Additional randomised controlled trials investigating the eﬀects of
vitamin D on risk of acute respiratory tract infection are
ongoing, and inclusion of data from these studies in
future meta-analyses has the potential to increase statistical power to test for subgroup eﬀects. However, all
three of the largest such studies (NCT01169259,
ACTRN12611000402943, and ACTRN12613000743763) are
being conducted in populations where profound vitamin D deficiency is rare, and two are using intermittent
bolus dosing regimens: the results are therefore unlikely
12

to alter our finding of benefit in people who are very deficient in vitamin D or in those receiving daily or weekly
supplementation. A third potential limitation is that
data relating to adherence to study drugs were not available for all participants. However, inclusion of non-adherent participants would bias results of our intention to
treat analysis towards the null: thus we conclude that
eﬀects of vitamin D in those who are fully adherent to
supplementation will be no less than those reported for
the study population overall. Finally, we caution that
study definitions of acute respiratory tract infection
were diverse, and virological, microbiological, or radiological confirmation was obtained for the minority of
events. Acute respiratory tract infection is often a clinical diagnosis in practice, however, and since all studies
were double blind and placebo controlled, diﬀerences in
incidence of events between study arms cannot be
attributed to observation bias.

Conclusions and policy implications
Our study reports a major new indication for vitamin D
supplementation: the prevention of acute respiratory
tract infection. We also show that people who are very
deficient in vitamin D and those receiving daily or
weekly supplementation without additional bolus
doses experienced particular benefit. Our results add to
the body of evidence supporting the introduction of
public health measures such as food fortification to
improve vitamin D status, particularly in settings where
profound vitamin D deficiency is common.
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